Rutgers scientists have used a diagnostic technique for the first time in the opioid addiction field that they believe has the potential to determine which opioid-addicted patients are more likely to relapse.
Few patients with alcohol-use problems who might benefit from either pharmacotherapy or specialized addiction treatment typically receive care. That may now change owing to a pilot study which examined the feasibility of providing a real-time video consultation resource in primary care. The study’s findings will be shared at the 44th annual scientific meeting of the Research Society on Alcoholism (RSA), which will be held virtually this year from the 19th - 23rd of June 2021 due to the COVID-19 pandemic.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen provide better pain control and have fewer adverse effects than codeine, a commonly prescribed opioid, when prescribed after outpatient surgery, according to new research published in CMAJ (Canadian Medical Association Journal) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.201915.
A discovery from researchers at the University of Illinois Chicago may lead to new treatments for individuals who suffer from alcohol use disorder and depression. The study, “Transcriptomics identifies STAT3 as a key regulator of hippocampal gene expression and anhedonia during withdrawal from chronic alcohol exposure,” is published in the journal Translational Psychiatry by researchers at UIC’s Center for Alcohol Research in Epigenetics.
An emotion regulation strategy known as cognitive reappraisal helped reduce the typically heightened and habitual attention to drug-related cues and contexts in cocaine-addicted individuals, a study by Mount Sinai researchers has found.
Researchers at the University of Illinois Chicago are a step closer to discovering why it is so difficult for people to withdraw from some antidepressant medications. The paper “Antidepressants produce persistent Gαs associated signaling changes in lipid rafts following drug withdrawal,” published in the journal Molecular Pharmacology, addresses the molecular and cellular mechanisms that cause antidepressant withdrawal syndrome.
o help increase access to the availability of non-opioid pain management treatments, the American Association of Nurse Anesthetists (AANA) supports the recent introduction of the Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act introduced by U.S. Rep. Terri Sewell (D-AL), along with Reps. David McKinley (R-WV), Ann Kuster (D-NH), and Brian Fitzpatrick (R-PA). The Senate version of this legislation (S. 589) was previously introduced.
Now that a key policy regarding prescription of a medication for opioid use disorder has been changed, experts reflect on the remaining challenges standing in the way of more people getting effective medication-assisted treatment, and discuss efforts to overcome those barriers.
Researchers at University of California San Diego School of Medicine found that functional impairments among adults aged 50 and older are associated with a higher risk of medical cannabis use; and prescription opioid and tranquilizer/sedative use and misuse.
A study published in the scientific journal Addiction provides the most comprehensive evidence to date of the association between recreational cannabis laws (RCLs) in US states and responses in the illegal markets for cannabis, heroin, and other drugs in those states.
Amid the rising toll of opioid overdoses and deaths in the U.S., several states are considering laws enabling civil commitment for involuntary treatment of patients with substance use disorders (SUDs). Most addiction medicine physicians support civil commitment for SUD treatment – but others strongly oppose this approach, reports a survey study in Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM). The journal is published in the Lippincott portfolio by Wolters Kluwer.
In a new study, clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) analyzed naloxone prescription trends during the COVID-19 pandemic in the United States and compared them to trends in opioid prescriptions and to overall prescriptions.
Neighborhoods without opioid treatment providers likely serve as a widespread barrier to care for those who are ready to seek help, a new study has found. Nearby access, including by public transit, is essential to treatment success, researchers say.
Researchers successfully used a protein called parapinopsin to turn off brain circuits. This protein is found in lamprey – an ancient lineage of jawless fish similar to eel. Researchers said the ability to inhibit neurons could eventually lead to turning off mood disorders and unwanted behaviors like depression and addiction.
The U.S. Food and Drug Administration’s proposed ban on menthol-flavored cigarettes and all flavored cigars could be particularly beneficial for Black and young people, says an expert on tobacco control at Washington University in St. Louis.“Around 80% of adult Black smokers and more than half of people age 18-34 use menthol brands,” said Todd Combs, research assistant professor at the Brown School who works on the Advancing Science & Practice in the Retail Environment (ASPiRE) project, which uses agent-based modeling to test the potential impact of retail tobacco policies.
Babies born to mothers diagnosed with cannabis use disorder are more likely to experience negative health outcomes, such as preterm birth and low birth weight, than babies born to mothers without a cannabis use disorder diagnosis, report UC San Diego researchers.
Policies designed to prevent the misuse of opioids may have the unintended side effect of limiting access to the pain-relieving drugs by terminally ill patients nearing the end of their life, new research led by the Oregon State University College of Pharmacy suggests.
June 2021 AJPH Issue highlights COVID-19 concerns in relation to fatal drug overdoses, drops in youth e-cigarette use, importance of public health measures, and strategies to protect correctional staff.
COVID-19 has been associated with increases in opioid overdose deaths, which may be in part because the pandemic limited access to buprenorphine, a treatment used for opioid dependency, according to a new study led by Princeton University researchers.
A comprehensive analysis of 80 scientific studies has identified a 'window of impairment' of between three and 10 hours caused by moderate to high doses of the intoxicating component of cannabis, tetrahydrocannabinol (THC).
Since 2016, a federal regulation has allowed nurse practitioners and physician assistants to obtain a waiver to prescribe buprenorphine, a medication used to treat opioid use disorder as a medication assisted treatment.
In a new study, nearly two-thirds of female participants reported drinking more since the beginning of the COVID-19 pandemic, including increases in daily drinking, drinking earlier in the day, and binge drinking.
Among people with opioid use disorder (OUD), more than half have reported contact with the criminal justice system. A new study published today in Health Affairs reveals that Medicaid expansion is associated with substantial improvements in access to medications for OUD. However, the study also reveals that individuals referred for treatment by the criminal justice system were substantially less likely to receive medications for OUD as part of the treatment plan.
UC San Diego School of Medicine researchers report that opioid users who participated in a 12-step abstinence program and recently stopped using drugs refused to take home naloxone, even if having it on hand might save lives.
Each year in the U.S., about 30 million hospitalizations occur in individuals 18 and older. Of these, more than 7 million are current cigarette smokers whose average hospital stay is several days. Researchers say that starting smoking cessation therapy during hospitalization and maintaining high adherence post-discharge can markedly improve permanent quit rates in these patients with minimal to no side effects. Cessation therapy also should include long-term counseling and at least 90 days of a prescription drug, specifically, varenicline.
The Arkansas Society of Anesthesiologists (ARSA) and the American Society of Anesthesiologists (ASA) today applaud bill sponsor Sen. Cecile Bledsoe and the Arkansas Senate Public Health, Labor and Welfare Committee for helping to ensure the safety of patients prescribed opioids. Arkansas State Drug Director Kirk Lane and Jonathan Goree, M.D., a physician anesthesiologist and pain medicine specialist, testified for the bill.